Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2018 08:00 ET | Source: Novan, Inc.

Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...
August 20, 2018 06:30 ET | Source: Novan, Inc.

Novan Announces Promising Clinical Results with SB414

In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
May 15, 2018 08:10 ET | Source: Novan, Inc.

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
February 13, 2018 08:05 ET | Source: Novan, Inc.

Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne

MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term...
December 05, 2017 08:35 ET | Source: Novan, Inc.

Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
October 18, 2017 07:05 ET | Source: Novan, Inc.

Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
July 07, 2017 09:05 ET | Source: Novan, Inc.

Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology

MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational...
April 27, 2017 09:05 ET | Source: Novan, Inc.

Novan Presents Preclinical Data from Inflammatory Skin Diseases Program

MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...
April 04, 2017 09:05 ET | Source: Novan, Inc.

Novan Welcomes Key Opinion Leaders to New Advisory Council

MORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion...
November 16, 2016 09:05 ET | Source: Novan, Inc.

Novan Announces Preclinical Data Demonstrating Immunomodulatory Effect In Vivo

Topical Application of SB414 Inhibited IL-17 in Psoriasis Mouse Model Effect Relates to Multiple Inflammatory Skin Diseases MORRISVILLE, N.C., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the...